Lecithin-cholesterol acyltransferase: Role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis

Current Opinion in Lipidology

Volumn 11, Issue 3, 2000, Pages 267-275

  Santamarina Fojo, Silvia ^a,b   Lambert, Gilles ^a   Hoeg, Jeffrey M ^a   Brewer Jr , H Bryan ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; ENZYME DEFICIENCY; GENE TRANSFER; GLOMERULOSCLEROSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; REVIEW; RISK;

ANIMALS; ARTERIOSCLEROSIS; BIOLOGICAL TRANSPORT; CHOLESTEROL; GENE TRANSFER TECHNIQUES; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; LIPOPROTEINS; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE;

ANIMALIA;

EID: 0034087304     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200006000-00007     Document Type: Review

References (80)

1. 1 Santamarina-Fojo S, Hoeg JM, Assmann G, Brewer Jr HB. Lecithin cholesterol acyltransferase deficiency and fish eye disease. In: The metabolic and molecular basis of inherited disease, 8th ed. Scriver CR, Beaudet AL, Sly WS, Valle D (editors). New York: McGraw-Hill; 2000 (in press).
2. 2 Jonas A. Regulation of lecithin cholesterol acyltransferase activity. Prog Lipid Res 1998; 37:209-234. This excellent review discusses the structure and function of human LCAT, with a special emphasis on the molecular and biochemical aspects of LCAT regulation by apoA-I.
3. 3 Dobiasova M, Frohlich JJ. Advances in understanding of the role of lecithin cholesterol acyltransferase (LCAT) in cholesterol transport. Clin Chim Acta 1999; 286:257-271. This excellent review describes the advances in LCAT molecular genetics, with a special emphasis on the latest development in assessment of LCAT activity as an indication of atherogenic risk.
4. 4 Applebaum-Bowden D. Lipases and lecithin: cholesterol acyltransferase in the control of lipoprotein metabolism. Curr Opin Lipidol 1995; 6:130-135.
5. 5 Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 1997; 38:191-205.
6. 6 Peelman F, Vinaimont N, Verhee A, Vanloo B, Verschelde JL, Labeur C, et al. A proposed architecture for lecithin cholesterol acyl transferase (LCAT): identification of the catalytic triad and molecular modeling. Protein Sci 1998; 7:587-599. On the basis of molecular modeling studies, the authors propose that LCAT belongs to the α/β hydrolase family, with a central domain consisting of seven conserved, mostly parallel β-strands surrounded by four α-helices, and separated by loops linking the β-strands.
7. 7 Peelman F, Vandekerckhove J, Rosseneu M. Structure and function of LCAT: new insights from structural predictions and animal models. Curr Opin Lipidol 2000; 11:155-160. This is an excellent review that summarizes the proposed LCAT structural motifs and discusses the impacts of FLD and FED point mutations on the overall structure of the enzyme.
8. 8 Rader DJ, Ikewaki K, Duverger N, Schmidt H, Pritchard H, Frohlich J, et al. Markedly accelerated catabolism of apolipoprotein A-II (ApoA-IIl) and high density lipoproteins containing ApoA-II in classic lecithin:cholesterol acyltransferase deficiency and fish-eye disease. J Clin Invest 1994; 93:321-330.
9. 9 Sakai N, Vaisman BL, Koch CA, Hoyt Jr RF, Meyn SM, Talley GD, et al. Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT) gene. J Biol Chem 1997; 272:7506-7510.
10. 10 Ng DS, Francone OL, Forte TM, Zhang J, Haghpassand M, Rubin EM. Disruption of the murine lecithin:cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I. J Biol Chem 1997; 272:15777-15781.
11. 11 Sakai N, Vaisman BL, Koch CA, Paiz JA, Brewer Jr HB, Santamarina-Fojo S. Analysis of aortic atherosclerosis and glomerulosclerosis in LCAT knockout mice [abstract]. Circulation 1997; 96:1-229.
12. 12 Forte TM, Oda MN, Knoff L, Frei B, Suh J, Harmony JAK, et al. Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration. J Lipid Res 1999; 40:1276-1283. Hypoalphalipoproteinemia in LCAT knockout mice is associated with decreased paraoxonase and platelet-activating factor activities, but increased apoJ levels.
13. 13 Teh EM, Chisholm JW, Dolphin PJ, Pouliquen Y, Savoldelli M, De Gennes JL, Benlian P. Classical LCAT deficiency resulting from a novel homozygous dinucleotide deletion in exon 4 of the human lecithin:cholesterol acyltransferase gene causing a frameshift and stop codon at residue 144. Atherosclerosis 1999; 146:141-151.
14. 14 Yang X-P, Inazu A, Honjo A, Koizumi I, Kajinami K, Koizumi J, et al. Catalytically inactive lecithin:cholesterol acyltransferase (LCAT) caused by a Gly 30 to Ser mutation in a family with LCAT deficiency. J Lipid Res 1997; 38:585-591.
15. 15 Klein H-G, Lohse P, Duverger N, Albers JJ, Rader DJ, Zech LA, et al. Two different allelic mutations in the lecithin:cholesterol acyltransferase (LCAT) gene resulting in classic LCAT deficiency: LCAT (tyr83-> stop) and LCAT (tyr156-> asn). J Lipid Res 1993; 34:49-58.
16. 16 Forte T, Nichols A, Glomset J, Norum K. The ultrastructure of plasma lipoproteins in lecithin:cholesterol acyltransferase deficiency. Scand J Clin Lab Invest Suppl 1974; 137:121-132.
17. 17 Ritland S, Gjone E. Quantitative studies of lipoprotein-X in familial lecithin: cholesterol acyltransferase deficiency and during cholesterol esterification. Clin Chim Acta 1975; 59:109-119.
18. 18 O K, Ly M, Fang DZ, Frohlich J, Choy PC. Effect of lipoprotein-X on lipid metabolism in rat kidney. Mol Cell Biochem 1997; 173:17-24.
19. 19 Lynn EG, Choy PC, Magil A, O K. Uptake and metabolism of lipoprotein-X in mesangial cells. Mol Cell Biochem 1997; 175:187-194.
20. 20 Gjone E, Blomhoff JP, Skarbovik AJ. Possible association between an abnormal low density lipoprotein and nephropathy in lecithin: cholesterol acyltransferase deficiency. Clin Chim Acta 1974; 54:11-18.
21. 21 Hoeg JM, Vaisman BL, Demosky Jr SJ, Meyn SM, Talley GD, Hoyt Jr RF, et al. Lecithin:cholesterol acyltransferase overexpression generates hyperalphalipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem 1996; 271:4396-4402.
22. 22 Vaisman BL, Klein H-G, Rouis M, Berard AM, Kindt MR, Talley GD, et al. Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J Biol Chem 1995; 270:12269-12275.
23. 23 Francone OL, Gong EL, Ng DS, Fielding CJ, Rubin EM. Expression of human lecithin-cholesterol acyltransferase in transgenic mice: effect of human apolipoprotein AI and human apolipoprotein AII on plasma lipoprotein cholesterol metabolism. J Clin Invest 1995; 96:1440-1448.
24. 24 Mehlum A, Staels B, Duverger N, Tailleux A, Castro G, Fievet C, et al. Tissue-specific expression of the human gene for lecithin-cholesterol acyltransferase in transgenic mice alters blood lipids, lipoproteins and lipases towards a less atherogenic profile. Eur J Biochem 1995; 230:567-575.
25. 25 Amar MJA, Vaisman BL, Koch CA, Paiz JA, Meyn SM, Fruchart-Najib J, et al. Expression of murine LCAT in transgenic mice; evaluation of the role of LCAT cholesteryl ester-fatty acid specificity in the development of atherosclerosis. Circulation 1999; 100:1-401.[abstract]
26. 26 Amar MJA, Shamburek RD, Foger B, Hoyt Jr RF, Wood DO, Santamarina-Fojo S, Brewer Jr HB. Adenovirus-mediated expression of LCAT in non-human primates leads to an antiatherogenic lipoprotein profile with increased HDL and decreased LDL. Circulation 1998; 98:1-35. [abstract]
27. 27 Brousseau ME, Santamarina-Fojo S, Zech LA, Berard AM, Vaisman BL, Meyn SM, et al. Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits: in vivo apolipoprotein A-I catabolism is delayed in a gene dose-dependent manner. J Clin Invest 1996; 97:1844-1851.
28. 28 Brousseau ME, Santamarina-Fojo S, Vaisman BL, Applebaum-Bowden D, Berard AM, Talley GD, et al. Overexpression of human lecithin:cholesterol acyltransferase in cholesterol-fed rabbits: LDL metabolism and HDL metabolism are affected in a gene dose-dependent manner. J Lipid Res 1997; 38:2537-2547.
29. 29 Foger B, Chase M, Amar MJ, Vaisman BL, Shamburek RD, Paigen B, et al. Cholesteryl ester transfer protein corrects dysfunctional HDL and reduces aortic atherosclerosis in lecithin:cholesterol acyltransferase (LCAT)-transgenic mice. J Biol Chem 1999; 274:36912-36920. CETP reduces atherosclerosis in human LCAT transgenic mice, an animal model with enhanced atherogenic risk due to impaired reverse cholesterol transport, by reversing the dysfunctional properties of LCAT transgenic mouse HDL. This study provides novel in-vivo evidence for a role for CETP in reverse cholesterol transport.
30. 30 Amar MJ, Vaisman BL, Foger B, Paigen B, Talley GD, Brewer Jr HB, Santamarina-Fojo S. The effect of hepatic lipase deficiency on the plasma lipids, lipoproteins and diet-induced atherosclerosis in LCAT transgenic mice. Circulation 1997; 96:1-109.[abstract]
31. 31 Berard AM, Remaley AT, Vaisman BL, Paigen B, Hoyt Jr RF, Meyn SM, et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin cholesteryl acyltransferase. Nature Med 1997; 3:744-749.
32. 32 Dugi KA, Vaisman BL, Sakai N, Knapper CL, Meyn SM, Brewer Jr HB, Santamarina-Fojo S. Adenovirus-mediated expression of hepatic lipase in LCAT transgenic mice. J Lipid Res 1997, 38:1822-1832.
33. 33 Sequret-Mace S, Latta-Mahieu M, Castro G, Luc G, Fruchart J-C, Rubin E, et al. Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemia patients with adenovirus-mediated transfer of human LCAT gene. Circulation 1996; 94:2177-2184.
34. 34 Foger B, Vaisman BL, Koch CA, Allen DT, Paiz JA, Paigen B, et al. Expression of human apoA-I abolishes aortic atherosclerosis in LCAT-transgenic mice. Circulation 1998; 1-450. [abstract]
35. 35 Brousseau ME, Wang J, Demosky Jr SJ, Vaisman BL, Talley GD, Santamarina-Fojo S, et al. Correction of hypoalphalipoproteinemia in LDL receptor-deficient rabbits by lecithin:cholesterol acyltransferase. J Lipid Res 1998; 39:1558-1567.
36. 36 Albers JJ, Bergelin RO, Adolphson JL, Wahl PW. Population-based reference values for lecithin-cholesterol acyltransferase (LCAT). Atherosclerosis 1982; 43:369-379.
37. 37 Albers JJ, Chen CH, Adolphson JL. Lecithin:cholesterol acyltransferase (LCAT) mass; its relationship to LCAT activity and cholesterol esterification rate. J Lipid Res 1981; 22:1206-1213.
38. 38 Mowri H-O, Patsch JR, Ritsch A, Föger B, Brown S, Patsch W. High density lipoproteins with differing apolipoproteins: relationships to postprandial lipemia, cholesteryl ester transfer protein, and activities of lipoprotein lipase, hepatic lipase, and lecithin:cholesterol acyltransferase. J Lipid Res 1994; 35:291-300.
39. 39 Tato F, Vega GL, Grundy SM. Determinants of plasma HDL-cholesterol in hypertriglyceridemic patients: role of cholesterol-ester transfer protein and lecithin cholesteryl acyltransferase. Arterioscler Thromb Vasc Biol 1997; 17:56-63.
40. 40 Solajic-Bozicevic N, Stavljenic A, Sesto M. Lecithin : cholesterol acyltransferase activity in patients with acute myocardial infarction and coronary heart disease. Artery 1991; 18:326-340.
41. 41 Solajic-Bozicevic N, Stavljenic-Rukavina A, Sesto M. Lecithin-cholesterol acyltransferase activity in patients with coronary artery disease examined by coronary angiography. Clin Investig 1994; 72:951-956.
42. 42 Miller NE, Rajput-Williams J, Nanjee MN, Samuel L, Albers JJ. Relationship of high density lipoprotein composition to plasma lecithin:cholesterol acyltransferase concentration in men. Atherosclerosis 1988; 69:123-129.
43. 43 Williams PT, Albers JJ, Krauss RM, Wood PD. Associations of lecithin: cholesterol acyltransferase (LCAT) mass concentrations with exercise, weight loss, and plasma lipoprotein subfraction concentrations in men. Atherosclerosis 1990; 82:53-58.
44. 44 Hoeg JM, Santamarina-Fojo S, Berard AM, Cornhill JF, Herderick EE, Feldman SJ, et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci USA 1996; 93:11448-11453.
45. 45 Brousseau ME, Kauffman RD, Herderick EE, Demosky Jr SJ, Evans W, Marcovina S, et al. LCAT modulates atherogenic plasma lipoproteins and the extent of atherosclerosis only in the presence of normal LDL receptors in transgenic rabbits. Arterioscler Thromb Vasc Biol 2000; 20:450-458. LCAT reduces the plasma levels of apoB-containing lipoproteins and development of atherosclerosis in transgenic rabbits by upregulation of the LDL receptor.
46. 46 Kuo PC, Rudd MA, Nicolosi R, Loscalzo J. Effect of dietary fat saturation and cholesterol on low density lipoprotein degradation by mononuclear cells of Cebus monkeys. Arteriosclerosis 1989; 9:919-927.
47. 47 Vohl MC, Neville TA, Kumarathasan R, Braschi S, Sparks DL. A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation of oxidized lipids during lipoprotein oxidation. Biochem 1999; 38:5976-5981. This study establishes that the antiatherogenic role of HDL in preventing the oxidation of LDL is due to LCAT on the HDL particles. Thus, LCAT functions in lipoprotein metabolism as a phospholipase, acyltransferase in cholesterol esterification, as well as antioxidant preventing the accumulation of oxidized lipids in plasma lipoproteins.
48. 48 Jimi S, Uesugi N, Saku K, Itabe H, Zhang B, Arakawa K, Takebayashi S. Possible induction of renal dysfunction in patients with lecithin:cholesterol acyltransferase deficiency by oxidized phosphatidylcholine in glomeruli. Arterioscler Thromb Vasc Biol 1999; 19:794-801. Identification of oxidized phospholipids as a potential cause of renal dysfunction in FLD is described.
49. 49 Glomset JA. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res 1968; 9:155-167.
50. 50 Goldstein JL, Hazzard WR, Schrott HG, Bierman EL, Motulsky AG, Levinski MJ, Campbell ED. Hyperlipidemia in coronary heart disease: I. lipid levels in 500 survivors of myocardial infarction. J Clin Invest 1973; 52:1533-1543.
51. 51 Dobiasova M. Lecithin:cholesterol acyltransferase and the regulation of endogenous cholesterol transport. Adv Lipid Res 1983; 20:107-194.
52. 52 Wells IC, Peitzmeier G, Vincent JK. Lecithin: cholesterol acyltransferase and lysolecithin in coronary atherosclerosis. Exp Mol Pathol 1986; 45:303-310.
53. 53 Tall AR. An overview of reverse cholesterol transport. Eur Heart J 1998; 19:A31-A35.
54. 54 Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36:211-228.
55. 55 Brooks-Wilson A, Marcil M, Clee SM, Zhang L-H, Roomp K, van Dam M, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genet 1999; 22:336-345. This study identifies mutations in the ABC1 gene as the underlying molecular defect in patients with Tangier disease.
56. 56 Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, et al. Tangier disease is caused by mutations in the ATP binding cassette transporter 1 (ABC1) gene. Nature Genet 1999; 22:352-355. This study identifies mutations in the ABC1 gene as the underlying molecular defect in patients with Tangier disease.
57. 57 Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nature Genet 1999; 22:347-351. This study identifies mutations in the ABC1 gene as the underlying molecular defect in patients with Tangier disease.
58. 58 Remaley AT, Rust S, Rosier M, Knapper C, Naudin L, Broccardo C, et al. Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. Proc Natl Acad Sci USA 1999; 96:12685-12690. A description is provided of the genomic organization of ABC1 and identification of the molecular defect in the ABC1 gene of patients from the original Tangier disease kindred.
59. 59 Kuivenhoven JA, van Voorst tot Voorst EJ, Wiebusch H, Marcovina SM, Funke M, Assmann G, et al. A unique genetic and biochemical presentation of fish-eye disease. J Clin Invest 1995; 96:2783-2791.
60. 60 Funke H, von Eckardstein A, Pritchard PH, Albers JJ, Kastelein JJP, Droste C, Assmann G. A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of α-LCAT activity. Proc Natl Acad Sci USA 1991; 88:4855-4859.
61. 61 Kuivenhoven JA, Stalenhoef AFH, Hill JS, Demacker PNM, Errami A, Kastelein JJP, Pritchard PH. Two novel molecular defects in the LCAT gene are associated with fish eye disease. Arterioscler Thromb Vasc Biol 1996; 16:294-303.
62. 62 Wiebusch H, Cullen P, Owen JS, Collins D, Sharp PS, Funke H, Assmann G. Deficiency of lecithin:cholesterol acyltransferase due to compound heterozygosity of two novel mutations (Gly33Arg and 30 bp ins) in the LCAT gene. Hum Mol Genet 1995; 4:143-145.
63. 63 Molhuizen HO, Brites FD, Petersen W, Fernandez K, Wikinski RW, Ayyobi AF, Kastelein JJP. A novel mutation in lecithin:cholesterol acyltransferase (LCAT) leading to fish-eye disease in South American female patient with proven coronary artery disease. Circulation 1999; 100:1-256.[abstract]
64. 64 Shamburek RD, Talley GD, Kindt MR, Kuivenhoven JA, Kastelein JJP, Stalenhoef AFH, Brewer Jr HB. Lecithin-cholesterol acyltransferase deficiency: human in vivo kinetics of LDL, apoA-I and apoA-II in partial LCAT deficiency (fish eye disease) with and without CAD. Circulation 1997; 96:1-723.[abstract]
65. 65 Mehlum A, Muri M, Hagve TA, Solberg LA, Prydz H. Mice overexpressing human lecithin:cholesterol acyltransferase are not protected against diet-induced atherosclerosis. Acta Pathologica, Microbiologica et Immunologica Scandinavia 1997; 105:861-868.
66. 66 Liu M, Bagdade JD, Subbaiah PV. Specificity of lecithin:cholesterol acyltransferase and atherogenic risk: comparative studies on the plasma composition and in vitro synthesis of cholesteryl esters in 14 vertebrate species. J Lipid Res 1995; 36:1813-1824.
67. 67 Pownall HJ, Pao Q, Massey JB. Acyl chain and headgroup specificity of human plasma lecithin:cholesterol acyltransferase. Separation of matrix and molecular specificities. J Biol Chem 1985; 260:2146-2152.
68. 68 Jonas A, Zorich NL, Kezdy KE, Trick WE. Reaction of discoidal complexes of apolipoprotein A-I and various phosphatidylcholines with lecithin cholesterol acyltransferase interfacial effects. J Biol Chem 1987; 262:3969-3974.
69. 69 Grove D, Pownall HJ. Comparative specificity of plasma lecithin:cholesterol acyltransferase from ten animal species. Lipids 1991; 26:416-420.
70. 70 Subbaiah PV, Liu M. Comparative studies on the substrate specificity of lecithin:cholesterol acyltransferase towards the molecular species of phosphatidylcholine in the plasma of 14 vertebrates. J Lipid Res 1996; 37:113-122.
71. 71 Cambien F, Warnet JM, Vernier V, Ducimetiere P, Jacqueson A, Flament C, et al. An epidemiology appraisal of the associations between the fatty acids esterifying serum cholesterol and some cardiovascular risk factors in middle-aged men. Am J Epidemiol 19B8; 127:75-86.
72. 72 Kingsbury KJ, Brett C, Stovold R, Chapman A, Anderson J, Morgan DM. Abnormal fatty acid composition and human atherosclerosis. Postgrad Med 1974; 50:425-440.
73. 73 Young F, Middleton CC. Correlation of arachidonic acid of sterol esters with restrictive and susceptibility to naturally-occurring atherosclerosis in pigeons. Proc Soc Exp Biol Med 1966; 123:816-819.
74. 74 Wen Y, Qian XX, Jia GL, Gao SB, Jin YF, Han DY, He SF. Correlation of serum lipids, lipoproteins, lipid peroxide products and metals with coronary heart disease. Chin Med J [Engl] 1993; 106:167-170.
75. 75 Foumier N, Atger V, Paul JL, de la Llera Moya M, Rothblat G, Moatti N. Fractional efflux and net change in cellular cholesterol content mediated by sera from mice expressing both human apolipoprotein AI and human lecithin:cholesterol acyltransferase genes. Atherosclerosis 1999; 147:227-235.
76. 76 Albanese M, Mancuso A, Talley GD, Yang W, Kruth HS, Santamarina-Fojo S, Brewer Jr HB. Effects of dysfunctional HDL on cholesterol efflux in LCAT transgenic mice. Circulation 1998; 98:1-450.[abstract]
77. 77 Itabe H, Hosoya R, Karasawa K, Jimi S, Saku K, Takebayashi S, Imanaka T, Takano T. Metabolism of oxidized phosphatidylcholines formed in oxidized low density lipoprotein by lecithin-cholesterol acyltransferase. J Biochem (Tokyo) 1999; 126:153-161.
78. 78 Bielicki JK, Forte TM. Evidence that lipid hydroperoxides inhibit plasma lecithin:cholesterol acyltransferase activity. J Lipid Res 1999; 40:948-954. Polar lipids isolated from minimally oxidized LDL dramatically inhibit LCAT activity. Phospholipid hydroperoxides were identified as the principal oxidized lipids from lipoxygenase-treated LDL, which effectively inhibits LCAT activity. This study was the first to show that phospholipid hydroperoxides may increase the atherogenic process by decreasing LCAT activity.
79. 79 Davit-Spraul A, Therond P, Leroy A, Palmade-Rieunier F, Rousset C, Moatti N, Legrand A. Inhibition of lecithin cholesterol acyltransferase by phosphatidylcholine hydroperoxides. FEBS Lett 1999; 447:106-110.
80. 80 Fan L, Owen JS, Dickson G. Construction and characterization of polycistronic retrovirus vectors for sustained and high-level co-expression of apolipoprotein A-I and lecithin-cholesterol acyltransferase. Atherosclerosis 1999; 147:139-145. A demonstration is provided that polycistronic retrovirus vectors containing the apoA-I and LCAT genes could be used to genetically modify myoblasts that can be transplanted back into skeletal muscle for expression. This represents a novel approach to the expression of genes to potentially decrease the development of atherosclerosis.